Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

79.16 +0.06 (+0.08%)
Official Closing Price Updated: 4:10 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Inflation Isn’t Going Away, But These Sectors Don’t Care
The CPI and PPI releases this week came in more or less at estimates - nothing to alarm the talking heads, anyway. They show inflation slowing down but not receding. 
Via Talk Markets
Topics ETFs Economy Stocks / Equities
How Do Investors Really Feel About Merck & Co?
Via Benzinga
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for mid-2025. 
Via Benzinga
Merck Injects $1 Billion To Expand Vaccine Production In US
Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and research investments. 
Via Benzinga
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains. 
Via MarketBeat
Merck & Co Unusual Options Activity For March 10
Via Benzinga
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
Via Benzinga
Decoding Merck & Co's Options Activity: What's the Big Picture?
Via Benzinga
Institutional Investors Bet $1B on These 4 Stocks—Should You?
Institutional investors snapped up at least $1 billion in shares of each of these four companies in Q4 of 2024 - should you buy as well? 
Via MarketBeat
3 Magnificent S&P 500 Dividend Stocks Down 20% to 63% to Buy and Hold Forever
Great investments are even better and more fruitful when you can buy them at a discount. 
Via The Motley Fool
Topics Stocks
5 Top Stocks to Buy for March
These 5 stocks look rather intriguing at current levels. 
Via The Motley Fool
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.
Discover MERCK & CO. INC., an undervalued stock. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
Is Merck Stock a Buy?
Via The Motley Fool
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst
In light of potential tariff threats from President Donald Trump, Pfizer Inc.'s (PFE.N) CEO Albert Bourla has suggested the possibility of shifting the company's overseas manufacturing to its U.S.... 
Via Benzinga
Topics Government World Trade
These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys. 
Via MarketBeat
Topics Stocks
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 36% to 64% to Buy and Hold Forever
The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake. 
Via The Motley Fool
Topics Stocks
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Via The Motley Fool
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
2 Healthcare Stocks with Big Upside and 1 to Skip
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks
Check out these three mega-cap names, valued over $200 billion each, that just authorized a combined $28 billion in buybacks. 
Via MarketBeat
Topics Earnings Economy Intellectual Property
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment. 
Via Stocktwits
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
Europe Approves Merck's Cancer Drug For Two Indications
Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.